Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Tactile Systems Technology (NASDAQ:TCMD).

For the full year 2025, CFO Birkemeyer reported, "we now expect total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year." The guidance ...

Tactile Systems (NASDAQ:TCMD) extended its post-market losses on Tuesday after the Minnesota-based MedTech fell short of Street forecasts for Q3 2024 revenue, prompting BTIG to downgrade its stock to ...

Shares of Tactile Systems Technology (NASDAQ: TCMD) fell as much as 18.5% early Tuesday, then settled to close down 3.2% after the medical technology company announced mixed quarterly results and ...

Tactile Systems Technology's fair value has remained steady at $16.83, even as its discount rate saw a slight uptick this period. Analysts attribute these developments to a balance between the company ...

Tactile Systems Technology (TCMD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

The latest price target for Tactile Systems Tech (NASDAQ:TCMD) was reported by Lake Street on November 4, 2025. The analyst firm set a price target for $32.00 expecting TCMD to rise to within 12 ...

Schematics of the tactile systems. (A) Schematics of the human and artificial tactile systems. (B) Examples of the functions of tactile systems. (Image: KIMM) The research team developed a real-time ...

The Company expects full year 2025 total revenue in the range of $316 million to $322 million, representing growth of approximately 8% to 10% year-over-year, compared to total revenue of $293.0 ...

When InvestingPro’s Fair Value model identified Tactile Systems Technology (NASDAQ:TCMD) as significantly undervalued on April 28, 2025, few investors could have predicted the healthcare company’s ...

Improved care has led to a much higher survival rate among cancer patients. It’s also produced an unintended consequence: the problem of how to treat lymphedema, the chronic swelling that occurs, ...